Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

Overview of attention for article published in Frontiers in oncology, February 2024

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,660 followers.

RT @FrontOncology: New research: Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy…

13 Feb 2024

Reply Repost Favourite

New research: Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3): Introduction Colorectal cancer… https://t.co

13 Feb 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.